Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2016-05-09 Regulatory Filings
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
FORM 8-K/A
Regulatory Filings Classification · 100% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It reports the entry into a material definitive agreement (a purchase agreement) and discloses relationships between directors and the counterparty. It includes details about the transaction but does not contain comprehensive financial statements or detailed financial analysis typical of annual or quarterly reports. The document is a current report amendment filing with the SEC, which is regulatory in nature and serves to update or correct prior disclosures. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement and amendment to a current report, not a full financial report or other specific filing type.
2016-05-09 English
PRIMARY DOCUMENT
Director's Dealing
2016-05-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 4, 2016, reporting two main items: (1) Entry into a Material Definitive Agreement regarding acquisition of synthetic royalties from CorMatrix, and (2) Results of Operations and Financial Condition, specifically a press release announcing financial results for the quarter ended March 31, 2016. The document includes a press release as Exhibit 99.1, which is the earnings release. The text explicitly states that the press release announces financial results for the quarter ended March 31, 2016, which corresponds to a quarterly earnings release. The document is not the full quarterly report (like a 10-Q) but an initial announcement of quarterly financial results. Therefore, the filing type is Earnings Release (ER). The document length (7442 characters) and content support this classification with high confidence.
2016-05-04 English
PRIMARY DOCUMENT
Director's Dealing
2016-05-03 English
Regulatory Filings 2016
Regulatory Filings
2016-04-18 English
FORM 4 SUBMISSION
Director's Dealing
2016-04-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.